StockData
TELA Bio, Inc. logo

TELA Bio, Inc. (TELA) stock

TELANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$0.78+0.02 (+2.36%)

Close on Nov 18, 2026Market cap $35.02MP/E –Yield –

TELA Bio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

TELA Bio's operating income for the twelve months ending Jun 30, 2026 was -$34.01M. For fiscal 2025 it was -$33.76M. The highest annual figure on record is -$16.92M in fiscal 2017.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$33.76M–
FY2024Dec 31, 2024-$34.12M–
FY2023Dec 31, 2023-$44.08M–
FY2022Dec 31, 2022-$39.01M–
FY2021Dec 31, 2021-$29.45M–
FY2020Dec 31, 2020-$25.28M–
FY2019Dec 31, 2019-$19.16M–
FY2018Dec 31, 2018-$17.78M–
FY2017Dec 31, 2017-$16.92M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.28M–
Q1 FY2026Mar 31, 2026-$10.53M–
Q4 FY2025Dec 31, 2025-$6.65M–
Q3 FY2025Sep 30, 2025-$7.55M–
Q2 FY2025Jun 30, 2025-$9.08M–
Q1 FY2025Mar 31, 2025-$10.47M–
Q4 FY2024Dec 31, 2024-$8.35M–
Q3 FY2024Sep 30, 2024-$9.37M–
Q2 FY2024Jun 30, 2024-$11.57M–
Q1 FY2024Mar 31, 2024-$4.83M–
Q4 FY2023Dec 31, 2023-$12.28M–
Q3 FY2023Sep 30, 2023-$10.18M–
Q2 FY2023Jun 30, 2023-$10.36M–
Q1 FY2023Mar 31, 2023-$11.25M–
Q4 FY2022Dec 31, 2022-$9.44M–
Q3 FY2022Sep 30, 2022-$9.49M–
Q2 FY2022Jun 30, 2022-$10.24M–
Q1 FY2022Mar 31, 2022-$9.84M–
Q4 FY2021Dec 31, 2021-$7.65M–
Q3 FY2021Sep 30, 2021-$7.22M–
Q2 FY2021Jun 30, 2021-$7.31M–
Q1 FY2021Mar 31, 2021-$7.27M–
Q4 FY2020Dec 31, 2020-$6.75M–
Q3 FY2020Sep 30, 2020-$6.86M–
Q2 FY2020Jun 30, 2020-$5.17M–
Q1 FY2020Mar 31, 2020-$6.50M–
Q2 FY2019Jun 30, 2019-$4.30M–
Q1 FY2019Mar 31, 2019-$5.18M–
Q4 FY2018Dec 31, 2018-$5.50M–
Q3 FY2018Sep 30, 2018-$2.52M–

More TELA Bio figures

See a number that looks wrong?